First Report of
            <i>bla</i>
            <sub>NDM-1</sub>
            in Raoultella ornithinolytica

Khajuria, Atul; Praharaj, Ashok Kumar; Grover, Naveen; Kumar, Manjit

doi:10.1128/aac.02147-12

Cited by 43 publications

(46 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a similar study which was done at a tertiary care hospital in the northeastern region of India, all the isolates of K. pneumoniae which were carbapenem resistant were found to harbour the bla NDM-1 gene [13]. We have also reported the first instance of the detection of the bla NDM-1 gene in a clinical isolate of Raoultella ornitholytica [14]. Previous studies have revealed that the genes which encoded NDM-1 were mostly located on plasmids and these studies had focused on the Enterobacteriaceae [15].…”

Section: Screening For the Carbapenemase Productionmentioning

confidence: 74%

Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India

Khajuria

Praharaj²,

Kumar³

et al. 2013

JCDR

Self Cite

View full text Add to dashboard Cite

Objective: The present study was undertaken to detect the prevalence of the bla NDM-1 metallo beta lactamases (MBLs) in the isolates of Pseudomonas aeruginosa, which were recovered from various clinical samples from hospitalized patients in a tertiary care centre in Pune, India. Methods:A total of 200 isolates of P. aeruginosa which were obtained from various clinical samples were subjected to antibiotic susceptibility testing by the disc-diffusion method and their MICs were determined by the Vitek -2 Automated Antimicrobial Identification and Susceptibility Testing System against imipenem, meropenem, ticarcillin, amikacin, gentamicin, tobramycin, ciprofloxacin, levofloxacin, moxifloxacin, tigecycline, trimethoprim/sulfamethoxazole, ampicillin/sulbactam, piperacillin/ tazobactam, cefoperazone/sulbactam, cefepime, tetracycline, ceftazidime, ceftriaxone and colistin. Their MICs were also determined by the Etest method against imipenem, meropenem, piperacillin, tobramycin, ceftazidime, tigecycline and colistin. The presence of bla NDM-1 was detected by PCR and it was confirmed by sequencing the gene which was present in the isolates which exhibited carbapenem resistance. The experimental transferability of the plasmids which carried bla NDM-1 was determined by using E. coli J53 as the recipient. Result:In the present study, four isolates of P. aeruginosa, which carried the bla NDM-1 gene, were resistant to imipenem and meropenem. These bla NDM-1 carrying isolates remained susceptible to colistin. The plasmid carrying bla NDM-1 was successfully transferred from the four isolates to E. coli J53 recipients. Conclusions:We are reporting the emergence of the P. aeruginosa carrying NDM-1gene, which exhibited resistance to imipenem and meropenem, for the first time from India.

show abstract

Section: Screening For the Carbapenemase Productionmentioning

confidence: 74%

Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India

Khajuria

Praharaj²,

Kumar³

et al. 2013

JCDR

Self Cite

View full text Add to dashboard Cite

show abstract

“…It appears that a majority of the cases that include clinical outcomes have predominantly been treated successfully, most often with colistin-and/or amikacin-based regimens (26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). It is likely that this collection of largely positive case reports is a result of publication bias and should be interpreted cautiously, since a small number of clinical failures with these same regimens have also been reported (6)(7)(8)40).…”

Section: Discussionmentioning

confidence: 99%

In VivoEfficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae

Wiskirchen

Nordmann

Crandon

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

e Doripenem and ertapenem have demonstrated efficacy against several NDM-1-producing isolates in vivo, despite having high MICs. In this study, we sought to further characterize the efficacy profiles of humanized regimens of standard (500 mg given every 8 h) and high-dose, prolonged infusion of doripenem (2 g given every 8 h, 4-h infusion) and 1 g of ertapenem given intravenously every 24 h and the comparator regimens of ceftazidime at 2 g given every 8 h (2-h infusion), levofloxacin at 500 mg every 24 h, and aztreonam at 2 g every 6 h (1-h infusion) against a wider range of isolates in a murine thigh infection model. An isogenic wild-type strain and NDM-1-producing Klebsiella pneumoniae and eight clinical NDM-1-producing members of the family Enterobacteriaceae were tested in immunocompetent-and neutropenic-mouse models. The wild-type strain was susceptible to all of the agents, while the isogenic NDM-1-producing strain was resistant to ceftazidime, doripenem, and ertapenem. Clinical NDM-1-producing strains were resistant to nearly all five of the agents (two were susceptible to levofloxacin). In immunocompetent mice, all of the agents produced >1-log 10 CFU reductions of the isogenic wild-type and NDM-1-producing strains after 24 h. Minimal efficacy of ceftazidime, aztreonam, and levofloxacin against the clinical NDM-1-producing strains was observed. However, despite in vitro resistance, >1-log 10 CFU reductions of six of eight clinical strains were achieved with high-dose, prolonged infusion of doripenem and ertapenem. Slight enhancements of doripenem activity over the standard doses were obtained with high-dose, prolonged infusion for three of the four isolates tested. Similar efficacy observations were noted in neutropenic mice. These data suggest that carbapenems are a viable treatment option for infections caused by NDM-1-producing Enterobacteriaceae. New Delhi metallo-␤-lactamase (NDM-1) is a novel carbapenemase that was first identified in a Klebsiella pneumoniae isolate in India in 2008 (1). Since then, it has disseminated at a high rate among Enterobacteriaceae isolates both within the Indian subcontinent and worldwide (2-4). The treatment options for infections caused by NDM-1-producing isolates are extremely limited, as these enzymes are known to hydrolyze penicillins, cephalosporins, and carbapenems while typically retaining susceptibility to only colistin and tigecycline (2), neither of which has been shown to be a dependable option on the basis of in vitro time-kill data and case reports (5-8). Aztreonam is not readily inactivated by metallo-␤-lactamases, including NDM-1, and may represent another potential option for therapy (1, 9). However, NDM-1-producing strains often coproduce other ␤-lactamases, such as CTX-M-and CMY-type enzymes, that possess the ability to hydrolyze aztreonam, further limiting the utility of all ␤-lactam antibiotics (1). Furthermore, in vivo efficacy data evaluating potential treatment options for NDM-1-producing isolates are sparse and clinical experience in treating inf...

show abstract

“…Few reports have described the emergence of carbapenemases in Raoultella, including IMP-8, OXA-48, and NDM-1 in R. planticola (18)(19)(20) and KPC and NDM-1 in R. ornithinolytica (21,22). Here, we report the first detection of a bla OXA-48 gene in an R. ornithinolytica clinical isolate.…”

mentioning

confidence: 67%

Whole-Genome Sequence of a bla _OXA-48 -Harboring Raoultella ornithinolytica Clinical Isolate from Lebanon

Al-Bayssari

Olaitan

Leangapichart

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We analyzed the whole-genome sequence of a bla OXA-48 -harboring Raoultella ornithinolytica clinical isolate from a patient in Lebanon. The size of the Raoultella ornithinolytica CMUL058 genome was 5,622,862 bp, with a G؉C content of 55.7%. We deciphered all the molecular mechanisms of antibiotic resistance, and we compared our genome to other available R. ornithinolytica genomes in GenBank. The resistome consisted of 9 antibiotic resistance genes, including a plasmidic bla OXA-48 gene whose genetic organization is also described. The genus Raoultella is composed of Gram-negative, oxidasenegative, catalase-positive, nonmotile, capsulated, facultatively anaerobic bacilli belonging to the family Enterobacteriaceae (1). It was initially classified in the genus Klebsiella, but the current taxonomy was established based on the analysis of the 16S rRNA and rpoB gene sequences, thus creating the new genus Raoultella (2). Members of the genus Raoultella include Raoultella electrica, R. terrigena, R. planticola, and R. ornithinolytica. R. ornithinolytica can be found in aquatic and hospital environments (3). Reports of R. ornithinolytica causing human infections are rare, but human bloodstream infections by this bacterium have been reported (4-6).Raoultella ornithinolytica CMUL058 was isolated from a stool sample from a 65-year-old male patient with Hodgkin lymphoma, during a study that was aimed at detecting carbapenemaseproducing bacteria in patients diagnosed with cancer in Lebanon. It was identified as R. ornithinolytica by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technique and by comparing its 16S rRNA gene sequence to the nucleotide database in NCBI using BLASTn, and the BLAST result of 99% showed the highest identity to R. ornithinolytica strain B6 (accession no. CP004142). The objective of the present study was to utilize whole-genome sequencing (WGS) to analyze the bacterial resistome, the genetic localization of the bla OXA-48 gene, and the specific features of this multidrugresistant R. ornithinolytica clinical isolate.Screening for carbapenemase production was carried out with the CarbaNP test (7), and molecular detection was carried out by PCR amplification for most of the carbapenemase genes using primers and PCR conditions previously described (8-10). R. ornithinolytica CMUL058 was found to be CarbaNP test positive, and PCR followed by sequencing showed that this strain harbors the bla OXA-48 gene.Genomic DNA of R. ornithinolytica CMUL058 was sequenced using Miseq Technology (Illumina Inc., San Diego, CA, USA) using the mate pair strategy. The assembly of the mate pair reads was done using A5-miseq and SPAdes (coverage 153 and 98, respectively). Mauve (11) was used to order the scaffolds and compare the genome with the closest related complete reference genome, that of R. ornithinolytica strain B6 (accession no. CP004142).Functional annotation of the assembled genome sequence was done using the RAST (Rapid Annotation using Subsystems Technology) server...

show abstract

First Report of bla _NDM-1 in Raoultella ornithinolytica

Cited by 43 publications

References 9 publications

Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India

Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India

In VivoEfficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae

Whole-Genome Sequence of a bla _OXA-48 -Harboring Raoultella ornithinolytica Clinical Isolate from Lebanon

Contact Info

Product

Resources

About

First Report of bla NDM-1 in Raoultella ornithinolytica

Cited by 43 publications

References 9 publications

Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India

Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India

In VivoEfficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae

Whole-Genome Sequence of a bla OXA-48 -Harboring Raoultella ornithinolytica Clinical Isolate from Lebanon

Contact Info

Product

Resources

About

First Report of bla _NDM-1 in Raoultella ornithinolytica

Whole-Genome Sequence of a bla _OXA-48 -Harboring Raoultella ornithinolytica Clinical Isolate from Lebanon